Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
NCT ID NCT07696715
First seen Jul 10, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This trial investigates whether giving standard combination immunotherapy (ipilimumab and nivolumab) in the early morning (before 10 AM) versus the afternoon (after 1 PM) improves tumor response in people with advanced melanoma. About 170 participants with metastatic or inoperable melanoma will be randomly assigned to one of the two timing schedules. The study aims to see if aligning treatment with the body's natural circadian rhythm can boost the immune system's ability to fight cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab and nivolumab (combination immunotherapy)
- What this could lead to
- If timing matters, this could lead to a simple change in when immunotherapy is given, potentially improving outcomes for melanoma patients without new drugs.
- What could go wrong
- This is a relatively small, open-label trial, so results may not be definitive. The effect of timing might be small or absent, and individual patient factors could influence outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Amsterdam UMC
Amsterdam, Netherlands
Contact
-
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Contact
-
ErasmusMC
Rotterdam, Netherlands
Contact
-
Leiden UMC
Leiden, Netherlands
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Could a lighter immunotherapy schedule keep advanced cancers in check?